Ian Flinn, MD: Bendamustine Plus Rituxmab Outperforms R-CHOP In Long-Term BRIGHT Follow-up

For patients with non-Hodgkin lymphomas, bendamustine plus rituximab extended survival and duration of response, compared with R-CHOP or R-CVP, according to 5-year follow-up data from the BRIGHT trial.

Видео Ian Flinn, MD: Bendamustine Plus Rituxmab Outperforms R-CHOP In Long-Term BRIGHT Follow-up канала American Society of Hematology